Tuberculosis (TB) is a serious public health issue, particularly in underdeveloped and developing countries.
Furthermore the first-line anti-TB treatments were established over 40 years ago, multidrug-resistant Mycobacterium tuberculosis
strains have been developed and the risk of coinfection with AIDS virus has highlighted this disease as a global
emergency. The urgent need for more effective treatments against multidrug-resistant strains compatible with anti-AIDS
drugs has prompted industries, governments and non-governmental agencies to pursue new drugs. In this study, we update
the portfolio listed at Stop TB Partnership, present the biological activities as well as structure-activity relationship for
these drugs and thoroughly discuss the synthetic methodologies used to produce these drugs.
Keywords: Tuberculosis, chemistry, medicinal chemistry, novel compounds, clinical trial, Mycobacterium tuberculosis.
open access plus
Rights & PermissionsPrintExport